Latest Articles

Publication Date
New drug approach offers hope for patients with recurrent aggressive cancers - AOL.com

New drug approach offers hope for patients with recurrent aggressive cancers AOL.com

Published: May 25, 2026, 1:36 a.m.
New drug approach offers hope for patients with recurrent aggressive cancers - MSN

New drug approach offers hope for patients with recurrent aggressive cancers MSN

Published: May 24, 2026, 10:05 p.m.
New drug approach offers hope for patients with recurrent aggressive cancers - Fox News

New drug approach offers hope for patients with recurrent aggressive cancers Fox News

Published: May 20, 2026, 11 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus - The ASCO Post

Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus The ASCO Post

Published: April 26, 2026, 9 p.m.
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer - CancerNetwork

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer CancerNetwork

Published: April 14, 2026, 8:09 p.m.
HER2 ADC Shows Promise in Recurrent Endometrial Cancer - Medscape

HER2 ADC Shows Promise in Recurrent Endometrial Cancer Medscape

Published: April 14, 2026, 11:41 a.m.
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks

BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks

Published: April 13, 2026, 12:29 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!